Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-215740
Filing Date
2026-05-11
Accepted
2026-05-11 07:49:18
Documents
75
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-20260331.htm   iXBRL 10-Q 2248821
2 EX-10.1 ntla-ex10_1.htm EX-10.1 58546
3 EX-10.2 ntla-ex10_2.htm EX-10.2 91443
4 EX-31.1 ntla-ex31_1.htm EX-31.1 15169
5 EX-31.2 ntla-ex31_2.htm EX-31.2 15189
6 EX-32.1 ntla-ex32_1.htm EX-32.1 10126
7 GRAPHIC gfx232172554_0.jpg GRAPHIC 659
8 GRAPHIC gfx231249033_0.jpg GRAPHIC 2247
  Complete submission text file 0001193125-26-215740.txt   9040482

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20260331.xsd EX-101.SCH 1230699
79 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20260331_htm.xml XML 1539953
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 26960908
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)